Secondary AML Treatment in Pediatric Patients
Please complete Pre-test
Chapter 1 of 1
Release Date: December 8, 2021
Expiration Date: December 8, 2022
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Join Dr. Kolb as he reviews secondary AML treatment options for pediatric patients. Topics include molecular aberrations in childhood AML, limitations of current treatment options (including treatment-related toxicity), and novel agents that may improve outcomes in pediatric patients with secondary AML.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Describe toxicities associated with traditional therapies for induction and consolidation chemotherapy in pediatric AML, and correlate the toxicities with prognoses and outcomes for patients
- Summarize efficacy and safety data for current and emerging agents for pediatric patients with newly diagnosed therapy-related AML and AML with myelodysplasia-related changes
- Outline the recommended treatment algorithm for secondary AML and align treatment with patient characteristics
Secondary AML Treatment in Pediatric Patients – E. Anders Kolb, MD
Instructions for Participation and Credit
This activity is eligible for credit through December 08, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
E. Anders Kolb, MD
Professor of Pediatrics
Sidney Kimmel Medical College at Thomas Jefferson University
Nemours Center for Cancer and Blood Disorders
Dr. E. Anders Kolb received his medical degree from Thomas Jefferson University in Philadelphia. He completed pediatric residency training at St. Christopher’s Hospital for Children and fellowship training in hematology/oncology in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center. He is Professor of Pediatrics at Sidney Kimmel Medical College at Thomas Jefferson University, and the Director at Nemours Center for Cancer and Blood Disorders, Wilmington, Delaware, one of the top U.S. children’s hospitals for pediatric oncology and hematology.
Dr. Kolb is certified by the American Board of Pediatrics and its sub-board in pediatric hematology/oncology. A national leader in the Children’s Oncology Group (COG), chairing its Myeloid Disease Committee and serving on its Scientific Council and Bone Tumor Committee, Dr. Kolb is also a member of COG’s Scientific Council. In addition, he is a member of the FDA Oncologic Drug Advisory Committee’s Pediatric Subcommittee and the National Heart, Lung and Blood Institute Bone Marrow Transplant Clinical Trials Network Data and Safety Monitoring Board. For the past year, he has served as co-chair of the LLS PedAL initiative, a master clinical trial that will simultaneously test multiple targeted therapies for children who face a relapse of their acute leukemia. Dr. Kolb serves as the Principal Investigator on the Nemours Children’s Health System National Cancer Institute Community Oncology Research Program and the Delaware Comprehensive Sickle Cell Center of Biomedical Research Excellence. Among his clinical and research interests are bone marrow transplantation, acute myeloid leukemia (AML), and drug development for children with leukemias.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Jazz Pharmaceuticals.
©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-044-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.|
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. E. Anders Kolb, faculty for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.